Cargando…
Open questions for Alzheimer’s disease immunotherapy
Perhaps more definitively than any other class of novel Alzheimer’s disease (AD) therapy, pre-clinical studies in mouse models of amyloid β (Aβ) deposition have established the disease-modifying potential of anti-Aβ immunotherapy. Despite disappointing results to date from anti-Aβ immunotherapy ther...
Autor principal: | Golde, Todd E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056616/ https://www.ncbi.nlm.nih.gov/pubmed/24393284 http://dx.doi.org/10.1186/alzrt233 |
Ejemplares similares
-
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
por: Golde, Todd E.
Publicado: (2022) -
Alzheimer’s disease – the journey of a healthy brain into organ failure
por: Golde, Todd E.
Publicado: (2022) -
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
por: Golde, Todd E, et al.
Publicado: (2013) -
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems
por: Galasko, Douglas, et al.
Publicado: (2013) -
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases
por: Golde, Todd E, et al.
Publicado: (2009)